一个新型的Everolimus涂层气球的3年临床随访,用于患有静脉静脉炎的患者
Fernando Alfonso1, Tamaz Shaburishvili2, Bruno Farah3
1Department of Cardiology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, IIS-IP, CIBER-CV, Madrid, Spain.
The American journal of cardiology
|February 27, 2026
概括
这项研究表明,一种新的药物涂层气球 (DCB) 对于治疗静脉静脉复缩 (ISR) 是安全有效的. 新型Everolimus-DCB在首次人体试验中表现出强的表现,在三年内持续获得好处.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 生物材料科学 生物材料科学
背景情况:
- 在心血管干预中,静脉静脉复缩 (ISR) 是一个重大挑战.
- 药物涂层气球 (DCB) 为ISR提供了一个无金属的治疗选择.
- 正在开发新的DCB配方,以改善结果.
研究的目的:
- 在ISR.患者中评估一种新型Everolimus药物涂层气球 (CVT-DCB) 的安全性和有效性.
- 评估主要安全终点,即180天后没有目标病变衰竭 (TLF).
- 为了确定内置支架晚期光损失 (LLL) 的初级疗效终点.
主要方法:
- 这是一项首次对人类进行的前性研究,涉及51名患有单个ISR病变的患者.
- 在9个欧洲地区注册了患者.
- 临床随访延长至三年,评估TLF和其他安全性/有效性参数.
主要成果:
- 实现了主要安全终点 (在180天后不受TLF影响),超过客观性能标准的比率为92.2%.
- 主要疗效终点 (LLL) 为0.40毫米,明显低于气球血管造形术的历史对照.
- 三年后的随访证实了持续的安全性和有效性,TLF率为9.8%,第一年后没有新的TVF事件.
结论:
- 这种新型的everolimus-DCB (CVT-DCB) 在治疗ISR.ISR.中显示出良好的安全性和有效性.
- 三年后持续的临床结果支持使用这种新的DCB技术.
- 这项研究提供了强有力的证据,证明CVT-DCB在ISR患者的长期性能.
相关概念视频
01:18Endocarditis III: Medical Management
292
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
292
01:26Mitral Stenosis III: Medical Management
376
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
376
01:25Mitral Regurgitation III: Medical Management
450
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
450
01:30Acute Coronary Syndrome III: Diagnostic Studies
338
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
338